OBJECTIVE: To review the available published data concerning the use of sublingual
immunotherapy (SLIT) in respiratory allergy to primarily evaluate the clinical efficacy and …

Sublingual immunotherapy (SLIT) for allergic respiratory diseases was first described in
1986 and immediately appeared as a viable alternative to the traditional subcutaneous …

Background Increasing interest in sublingual immunotherapy (SLIT) among practitioners
and patients has resulted in numerous publications and clinical trials in recent years. With …

Sublingual immunotherapy (SLIT) has been used with increasing frequency in Europe and
is viewed with increasing interest by allergists in the United States. To address this interest …

The acceptability of sublingual immunotherapy (SLIT) in guidelines or statements has
recently increased. SLIT is currently used in Europe, Asia, and Australia for the treatment of …

Since the early 1900s, allergen immunotherapy has been recognized as an effective
treatment option for patients with inhalant allergies. Subcutaneous injection has traditionally …

BACKGROUND: Sublingual immunotherapy (SLIT) has been proved to be effective in
allergic rhinitis and asthma, but there are few data on its preventive effects, especially in …

Specific allergen immunotherapy (SIT) is the only disease-modifying treatment for allergic
rhinitis and asthma. Subcutaneous immunotherapy (SCIT) is the only method with a US …

Present knowledge regarding the clinical efficacy and safety of sublingual immunotherapy
(SLIT) for the treatment of respiratory allergy is reviewed. Allergenspecific immunotherapy is …

Sublingual immunotherapy (SLIT) was accepted for clinical use by the medical community
only 15 years after the first controlled trial published. The acceptance of SLIT has been …